Filter

51 - 60 of 559 Results

  • FAQs on Medicare Financing and Trust Fund Solvency

    Issue Brief

    In discussions of Medicare’s financial condition, attention frequently centers on one specific measure—the solvency of the Medicare Hospital Insurance (HI) trust fund, out of which Medicare Part A benefits are paid. Based on current projections from the Medicare Board of Trustees, the HI trust fund is projected to be depleted in 2036, 12 years from now. These FAQs answer key questions about Medicare financing and trust fund solvency.

  • Donor Government Funding for Family Planning in 2022

    Report

    This report provides an analysis of donor government funding to address family planning in low- and middle-income countries in 2022, which totaled US$1.35 billion and was a decline of 9% (US$129 million) compared to the 2021 amount (US$1.48 billion). While the decline was due to decreases in funding by most donor governments, a significant share can be attributed to exchange rate fluctuations resulting from the rise in value of the U.S. dollar against most currencies during 2022.

  • Global Health Funding in the FY 2024 Final Appropriations Bill

    Fact Sheet

    Updated: March 25, 2024 On March 23, 2024, the President signed the second package of final FY 2024 appropriations bills, otherwise known as the “Further Consolidated Appropriations Act, 2024,” which was released by the House and Senate Appropriations Committees on March 20, 2024, passed by the House on March 22, 2024 and passed by the…

  • Gross Medicare Spending on Ozempic and Other GLP-1s Is Already Skyrocketing – Even Though Medicare Cannot Cover The Drugs for Weight Loss

    News Release

    A KFF analysis shows that gross total Medicare spending on Ozempic and other similar drugs has increased dramatically in recent years – even though Medicare is explicitly prohibited by law from covering the drugs for obesity. That’s because Medicare now covers the drugs, known as GLP-1s, for other medically accepted indications, including to treat diabetes.

  • Medicare Spending on Ozempic and Other GLP-1s Is Skyrocketing

    Policy Watch

    This policy watch analyzes the latest data on Medicare Part D spending on GLP-1 drugs, initially approved to treat diabetes but in high demand as treatments for obesity, and shows how spending on these drugs has increased substantially in recent years.